keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29054890/natural-killer-t-cell-immunotherapy-in-combination-with-chemotherapy-induced-immunogenic-cell-death-targets-metastatic-breast-cancer
#1
Simon Gebremeskel, Lynnea Lobert, Kaitlyn Tanner, Brynn Walker, Tora Oliphant, Livia E Clarke, Graham Dellaire, Brent Johnston
Natural killer T (NKT) cells are glycolipid-reactive lymphocytes that promote cancer control. In previous studies, NKT-cell activation improved survival and antitumor immunity in a post-surgical mouse model of metastatic breast cancer. Herein, we investigated whether NKT-cell activation could be combined with chemotherapeutic agents to augment therapeutic outcomes. Gemcitabine and cyclophosphamide analogs enhanced the potential immunogenicity of 4T1 mammary carcinoma cells by increasing the expression of antigen-presenting molecules (MHC-I, MHC-II, and CD1d) and promoting exposure or release of immunogenic cell death markers (calreticulin, HMGB1 and ATP)...
October 20, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/29052527/negative-genic-switch-of-her-2-in-the-primary-tumor-instead-of-the-synchronous-metastatic-nodal-lesions-after-neoadjuvant-chemotherapy-in-a-patient-with-primary-her2-positive-breast-cancer
#2
Hao-Ran Chen, Yu-Tuan Wu, Qiu-Bo Yu, Ya-Ying Yang, Yu-Xian Wei, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
BACKGROUND: A few retrospective studies have indicated that neoadjuvant chemotherapy (NAC) in breast cancer may change biomarker profiles of the primary tumor. Little is known about the status of HER-2 gene of the synchronous nodal metastases when that of the residual tumor undergoes negative conversion in a neoadjuvant setting. CASE PRESENTATION: We describe a female patient with left breast cancer (T2N2M0) who underwent negative conversion of HER-2 in the primary tumor instead of the synchronous nodal lesions after NAC...
October 19, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29048630/metastatic-genes-targeted-by-an-antioxidant-in-an-established-radiation-%C3%A2-and-estrogen-breast-cancer-model
#3
Gloria M Calaf, Debasish Roy
Breast cancer remains the second most common disease worldwide. Radiotherapy, alone or in combination with chemotherapy, is widely used after surgery as a treatment for cancer with proven therapeutic efficacy manifested by reduced incidence of loco-regional and distant recurrences. However, clinical evidence indicates that relapses occurring after radiotherapy are associated with increased metastatic potential and poor prognosis in the breast. Among the anticarcinogenic and antiproliferative agents, curcumin is a well-known major dietary natural yellow pigment derived from the rhizome of the herb Curcuma longa (Zingiberaceae)...
September 14, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29046098/infection-of-ptfe-mesh-15-years-following-pedicled-tram-flap-breast-reconstruction-mechanism-and-aetiology
#4
A Elfaki, A Gkorila, M Khatib, C M Malata
The pedicled transverse rectus abdominis myocutaneous (TRAM) flap procedure is still widely used for breast reconstruction. The repair of the flap harvest site in the transverse rectus abdominis muscle and sheath is often assisted by the use of prosthetic meshes. This decreases the risk of abdominal wall weakness and herniation but, being a foreign body, it also carries the risk of infection. In this report, we describe the case of a 63-year-old patient who, whilst receiving chemotherapy for metastatic breast cancer, presented with an infected polytetrafluoroethylene mesh 15 years after pedicled TRAM flap immediate breast reconstruction...
October 19, 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/29045554/veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus-placebo-with-carboplatin-paclitaxel-in-patients-with-brca1-2-locally-recurrent-metastatic-breast-cancer-randomized-phase-ii-study
#5
H S Han, V Diéras, M Robson, M Palácová, P K Marcom, A Jager, I Bondarenko, D Citrin, M Campone, M L Telli, S M Domchek, M Friedlander, B Kaufman, J E Garber, Y Shparyk, E Chmielowska, E H Jakobsen, V Kaklamani, W Gradishar, C K Ratajczak, C Nickner, Q Qin, J Qian, S P Shepherd, S J Isakoff, S Puhalla
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA damage repair. Veliparib, a potent PARP inhibitor, enhanced the antitumor activity of platinum agents and temozolomide in early phase clinical trials. This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29043567/impact-of-adverse-events-on-health-utility-and-health-related-quality-of-life-in-patients-receiving-first-line-chemotherapy-for-metastatic-breast-cancer-results-from-the-select-bc-study
#6
Yasuhiro Hagiwara, Takeru Shiroiwa, Kojiro Shimozuma, Takuya Kawahara, Yukari Uemura, Takanori Watanabe, Naruto Taira, Takashi Fukuda, Yasuo Ohashi, Hirofumi Mukai
OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation...
October 17, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29030786/routine-treatment-and-outcome-of-breast-cancer-in-younger-versus-elderly-patients-results-from-the-senora-project-of-the-prospective-german-tmk-cohort-study
#7
Thomas Fietz, Mark-Oliver Zahn, Andreas Köhler, Erik Engel, Melanie Frank, Lisa Kruggel, Martina Jänicke, Norbert Marschner
PURPOSE: There is an ongoing discussion about 'undertreatment' of breast cancer in elderly patients. Due to low accrual into clinical trials, level 1 evidence is scarce. We report prospective data of elderly patients with breast cancer treated by medical oncologists in Germany. METHODS: The SENORA project within the prospective cohort study TMK (Tumour Registry Breast Cancer) was conducted in 82 centres from 2007-2015. Among 2316 patients, half were enrolled with curative and half with palliative treatment intention...
October 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29029489/similar-response-profile-to-neoadjuvant-chemotherapy-but-different-survival-in-inflammatory-versus-locally-advanced-breast-cancers
#8
Audrey Monneur, Anthony Goncalves, Marine Gilabert, Pascal Finetti, Carole Tarpin, Christophe Zemmour, Jean-Marc Extra, Agnès Tallet, Eric Lambaudie, Jocelyne Jacquemier, Gilles Houvenaeghel, Jean-Marie Boher, Patrice Viens, François Bertucci
Inflammatory breast cancer (IBC) is a very aggressive form of breast cancer, as compared to locally advanced breast cancer (LABC). Neoadjuvant chemotherapy followed by surgery is the standard treatment in both cases. Whether IBC is less chemosensitive than LABC remains unclear. We retrospectively compared the rate of pathological complete response (pCR) to neoadjuvant chemotherapy in IBC and LABC. METHODS: Patients with IBC or LABC treated with neoadjuvant anthracycline-based chemotherapy followed by surgery were selected from our institutional database...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29027954/marine-sponge-natural-products-with-anticancer-potential-an-updated-review
#9
REVIEW
Cinzia Calcabrini, Elena Catanzaro, Anupam Bishayee, Eleonora Turrini, Carmela Fimognari
Despite the huge investment into research and the significant effort and advances made in the search for new anticancer drugs in recent decades, cancer cure and treatment continue to be a formidable challenge. Many sources, including plants, animals, and minerals, have been explored in the oncological field because of the possibility of identifying novel molecular therapeutics. Marine sponges are a prolific source of secondary metabolites, a number of which showed intriguing tumor chemopreventive and chemotherapeutic properties...
October 13, 2017: Marine Drugs
https://www.readbyqxmd.com/read/29027523/-role-of-tenascin-%C3%B0-in-triple-negative-breast-cancer
#10
O P Popova, S Yu Bogomazova, A A Ivanov
AIM: to establish a relationship between the main markers tumor stem cells (TSCs), CD44, and CD24, the level of tenascin C production, and chemoresistance in triple-negative breast cancer (BC). SUBJECTS AND METHODS: Thirty biopsy specimens from triple-negative BC patients who had conventionally received preoperative chemotherapy followed by surgery were selected in the investigation. All the selected patients were conventionally assigned to neoadjuvant polychemotherapy (PCT) with paclitaxel and carboplatin...
2017: Arkhiv Patologii
https://www.readbyqxmd.com/read/29027290/pertuzumab-and-trastuzumab-infusion-related-cytokine-release-syndrome-in-a-chemotherapy-naive-patient-with-metastatic-breast-cancer
#11
Adonice Khoury, Vikas Parihar, Lillie O'steen, Kartikeya Cherabuddi
Pertuzumab is a monoclonal antibody that targets and down regulates HER-2/neu expression in ductal breast tumors. Other HER-2/neu monoclonal antibodies, particularly trastuzumab, have been implicated to induce infusion related reactions such as cytokine release syndrome (CRS). Here, we report a case of pertuzumab associated CRS prior to infusion of trastuzumab which warranted hospitalization for symptom management.
October 13, 2017: Breast Journal
https://www.readbyqxmd.com/read/29027049/acute-phase-dynamics-of-circulating-tumor-cells-after-paclitaxel-and-doxorubicin-chemotherapy-in-breast-cancer-mouse-models
#12
Yayoi Adachi, Mayumi Yoshimura, Keiko Nishida, Hisanobu Usuki, Keiko Shibata, Masaya Hattori, Naoto Kondo, Yasushi Yatabe, Hiroji Iwata, Toyone Kikumori, Yasuhiro Kodera, Hayao Nakanishi
PURPOSE: Circulating tumor cells (CTCs) can provide a potentially minimal invasive source for monitoring chemotherapeutic effects. However, detailed in vivo dynamics of CTC after chemotherapy remain largely unknown. METHODS: We monitored CTC number and morphology early after chemotherapy using a newly developed cytology-based CTC detection device and triple-negative breast cancer mouse CTC models with spontaneous lung metastatic potential. RESULTS: Paclitaxel inhibited cell growth of breast cancer cells by mainly G2/M cell cycle arrest and partly apoptosis, whereas doxorubicin inhibited cell growth mainly by apoptosis and partly G2 cell cycle arrest in vitro...
October 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29021293/ppar%C3%AE-ligand-induced-annexin-a1-expression-determines-chemotherapy-response-via-deubiquitination-of-death-domain-kinase-rip-in-triple-negative-breast-cancers
#13
Luxi Chen, Yi Yuan, Shreya Kar, Madhu M Kanchi, Suruchi Arora, Ji E Kim, Pei F Koh, Einas Yousef, Ramar P Samy, Muthu K Shanmugam, Tuan Z Tan, Sung W Shin, Frank Arfuso, Han M Shen, Henry Yang, Boon C Goh, Joo I Park, Louis Gaboury, Peter E Lobie, Gautam Sethi, Lina H K Lim, Alan P Kumar
Metastatic breast cancer is still incurable so far; new specifically targeted and more effective therapies for triple-negative breast cancer (TNBC) are required in the clinic. In this study, our clinical data have established that basal and claudin-low subtypes of breast cancer (TNBC types) express significantly higher levels of Annexin A1 (ANXA1) with poor survival outcomes. Using human cancer cell lines that model the TNBC subtype, we observed a strong positive correlation between expression of ANXA1 and PPARγ...
August 15, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29020960/perspectives-in-immunotherapy-meeting-report-from-the-immunotherapy-bridge-napoli-november-30th-2016
#14
Paolo A Ascierto, Bruno Daniele, Hans Hammers, Vera Hirsh, Joseph Kim, Lisa Licitra, Rita Nanda, Sandro Pignata
The complex interactions between the immune system and tumors lead the identification of key molecules that govern these interactions: immunotherapeutics were designed to overcome the mechanisms broken by tumors to evade immune destruction. After the substantial advances in melanoma, immunotherapy currently includes many other type of cancers, but the melanoma lesson is essential to progress in other type of cancers, since immunotherapy is potentially improving clinical outcome in various solid and haematologic malignancies...
October 11, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28994557/increasing-survival-of-metastatic-breast-cancer-through-locoregional-surgery
#15
Begoña Díaz de la Noval, Laura Frías Aldeguer, María Á Leal García, Enrique García López, Mariana Díaz Almirón, María Herrera de la Muela
BACKGROUND: Surgery for the primary tumor in metastatic breast cancer is usually not recommended, assuming that local therapy provides no advantage. Recent reports suggest a survival improvement after locoregional treatment, but this is still controversial. We aimed to evaluate the effectiveness of locoregional treatment in primary metastatic breast cancer and to determine associated factors. METHODS: A retrospective analysis of 39 women with de novo metastatic breast cancer at Hospital Universitario La Paz, from January-2012 to June-2016 grouped by locoregional treatment (n=23) or not (n=16)...
October 9, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28994315/first-line-treatment-disruption-among-post-menopausal-women-with-hr-her2-metastatic-breast-cancer-a-retrospective-us-claims-study
#16
Derek H Tang, Nanxin Li, Ella X Du, Miranda Peeples, Lihao Chu, Jipan Xie, Victoria Barghout
OBJECTIVE: This study assessed disruption of first-line treatments initiated after the approval of the first CDK 4/6 inhibitor, palbociclib, among postmenopausal women with HR+/HER2- metastatic breast cancer (mBC) in the United States. METHODS: Postmenopausal women with HR+/HER2- mBC who initiated first-line endocrine therapy or chemotherapy (index therapy) between 3(rd) February 2015 (palbociclib approval date) and 29(th) February 2016 (end of data) were identified from the Symphony SourceLx database...
October 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28989927/metastatic-uterine-cancer-looking-as-cervical-fibroid-in-recurrent-breast-cancer-woman-a-case-report
#17
So Young Seo, Jin Yong Shin, Yong Il Ji
Metastasis to the female genital tract from extragenital primary cancer is uncommon. In this case, a 46-year-old woman was diagnosed with invasive lobular carcinoma of the left breast in 2011. She had left breast conserving surgery, chemotherapy, radiation, and hormonal therapy (gosereline and tamoxifen). However, she developed menorrhagia after interruption of hormonal therapy and incidentally, the ultrasonogram of her pelvis showed a solid, large mass in the cervix. It looked like leiomyoma. Because of massive vaginal bleeding requiring multiple blood transfusions, she underwent total hysterectomy with bilateral salpingo-oophorectomy...
September 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28988693/circulating-cd8-cd28-suppressor-t-cells-tied-to-poorer-prognosis-among-metastatic-breast-cancer-patients-receiving-adoptive-t-cell-therapy-a-cohort-study
#18
Qingkun Song, Jun Ren, Xinna Zhou, Xiaoli Wang, Guohong Song, Amy Hobeika, Yanhua Yuan, Herbert Kim Lyerly
BACKGROUND AIMS: This study aimed to determine the prognostic value of circulating CD8(+)CD28(-) T lymphocytes among breast cancer patients treated with adoptive T-lymphocyte immunotherapy after chemotherapy. METHODS: Two hundred and thirty-two breast cancer patients underwent adoptive T-cell immunotherapy. Circulating CD8(+)CD28(-) proportion was measured by flow cytometry. Median proportion of CD8(+)CD28(-) was 24.2% and set as the categorical cutoff value for further analysis...
October 4, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28988243/efficacy-in-treating-lung-metastasis-of-invasive-breast-cancer-with-functional-vincristine-plus-dasatinib-liposomes
#19
Fan Zeng, Rui-Jun Ju, Lei Liu, Hong-Jun Xie, Li-Min Mu, Wan-Liang Lu
BACKGROUND: The metastasis of breast cancer is the leading cause of death, while lung metastasis is a major clinical phenomenon in patients with invasive breast cancer. The current treatment option comprising surgery, radiation, and standard chemotherapy cannot achieve a satisfactory effect on the treatment of lung metastasis of breast cancer. In this study, we report the potential of preventing lung metastasis of invasive breast cancer using the newly developed functional vincristine plus dasatinib liposomes...
October 7, 2017: Pharmacology
https://www.readbyqxmd.com/read/28968585/treatment-and-prognosis-of-leptomeningeal-disease-secondary-to-metastatic-breast-cancer-a-single-centre-experience
#20
Belinda Kingston, Hamzeh Kayhanian, Chloe Brooks, Nicola Cox, Narda Chaabouni, Stefania Redana, Eleftheria Kalaitzaki, Ian Smith, Mary O'Brien, Stephen Johnston, Marina Parton, Jill Noble, Susie Stanway, Alistair Ring, Nicholas Turner, Alicia Okines
PURPOSE: Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment modalities, efficacy data are limited. This study was designed to evaluate potential predictors of survival in this patient group. METHODS: Breast cancer patients with LMD diagnosed by MRI in a 10-year period (2004-2014) were identified from electronic patient records...
September 29, 2017: Breast: Official Journal of the European Society of Mastology
keyword
keyword
117545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"